AbbVie Currently Down Seven Consecutive Days, on Pace for Longest Losing Streak Since September 2016 — Data Talk
AbbVie, Inc. (ABBV) is currently at $154.08, down $1.26 or 0.81%
--Would be lowest close since Dec. 21, 2023, when it closed at $152.59
--Currently down seven consecutive days; down 7.41% over this period
--Longest losing streak since Sept. 1, 2016, when it fell for nine straight trading days
--Worst seven day stretch since the seven days ending April 12, 2024, when it fell 8.49%
--Down 5.26% month-to-date
--Down 0.57% year-to-date
--Down 15.39% from its all-time closing high of $182.10 on March 28, 2024
--Up 11.68% from 52 weeks ago (May 31, 2023), when it closed at $137.96
--Down 15.39% from its 52-week closing high of $182.10 on March 28, 2024
--Up 16.28% from its 52-week closing low of $132.51 on June 28, 2023
--Traded as low as $153.99
--Down 0.87% at today's intraday low
All data as of 1:46:32 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
May 29, 2024 14:03 ET (18:03 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks